NASDAQ
ERNAW
Last Price
US $0.057
KEY FIGURES
MKT CAP
$447.6K
EPS
TTM$-10.36
EPS Growth (1Y)
-
PEG
TTMN/M
P/E
TTMN/M
P/S
TTM-
YIELD
-
GROWTH (5Y CAGR)
Revenue
-
EBITDA
-
Cash flow
Valuation
Financial
Performance
Cash flow to debt coverage
Ernexa Therapeutics Inc. Warrants cash flow to debt ratio of -1.43K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Debt-to-equity ratio
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Debt-to-equity trend
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Net debt to EBITDA
Ernexa Therapeutics Inc. Warrants has a net cash position, so leverage is healthy.
Interest coverage
Ernexa Therapeutics Inc. Warrants earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Current ratio
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Return on assets
Ernexa Therapeutics Inc. Warrants's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Ernexa Therapeutics Inc. Warrants's return on equity of -305.85%, is lower than 15.00%, indicating bad performance
Earnings quality
Ernexa Therapeutics Inc. Warrants's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Ernexa Therapeutics Inc. Warrants has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Ernexa Therapeutics Inc. Warrants has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Ernexa Therapeutics Inc. Warrants has negative free cash flow, indicating cash burn
Earnings growth
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Revenue growth
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Return on invested capital
ROIC -328.05% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Ernexa Therapeutics Inc. Warrants has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Ernexa Therapeutics Inc. Warrants has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Ernexa Therapeutics Inc. Warrants has insufficient public price history to evaluate ROE consistency.
Base Cash Flow Valuation (DCF)
Ernexa Therapeutics Inc. Warrants has insufficient data to evaluate this check.
Earnings yield (TTM)
Ernexa Therapeutics Inc. Warrants has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Base EBITDA Valuation
Ernexa Therapeutics Inc. Warrants is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model
EV/EBITDA (FY)
Ernexa Therapeutics Inc. Warrants has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Ernexa Therapeutics Inc. Warrants has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Ernexa Therapeutics Inc. Warrants has a price-to-book ratio of 0.02x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
Ernexa Therapeutics Inc. Warrants has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-305.85%
Return on equity
ROIC: -328.05%
Valuation History
-
Price to Earnings
EV/EBITDA: 0.19X
Cash flow
Profit margin
-
Fair Value
Market $0.057
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.